{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:42:37Z","timestamp":1763037757253,"version":"build-2065373602"},"reference-count":5,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.annonc.2022.06.002","type":"journal-article","created":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T13:36:44Z","timestamp":1655386604000},"page":"981-982","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Fewer cetuximab-related skin-toxicities in colorectal cancer patients treated with encorafenib: a Yin and Yang effect of ERK paradoxical activation"],"prefix":"10.1016","volume":"33","author":[{"given":"J.","family":"Ciccolini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Milano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.annonc.2022.06.002_bib1","doi-asserted-by":"crossref","first-page":"6329","DOI":"10.1158\/1078-0432.CCR-11-1081","article-title":"Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients","volume":"17","author":"Azzopardi","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2022.06.002_bib2","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.annonc.2019.10.001","article-title":"Relation of cetuximab-induced skin toxicity and early tumor shrinkage in metastatic colorectal cancer patients: results of the randomized phase 3 trial FIRE-3 (AIO KRK0306)","volume":"31","author":"Holch","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2022.06.002_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100328","article-title":"Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study","volume":"6","author":"Tabernero","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.annonc.2022.06.002_bib4","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nature08902","article-title":"RAF inhibitors transactivate RAF dimers\u00a0and ERK signalling in cells with wild-type BRAF","volume":"464","author":"Poulikakos","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.annonc.2022.06.002_bib5","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/jdv.15363","article-title":"The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in B-rapidly accelerated fibrosarcoma-mutated advanced melanoma","volume":"33","author":"Graf","year":"2019","journal-title":"J\u00a0Eur Acad Dermatol Venereol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375342201729X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375342201729X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T06:14:36Z","timestamp":1760336076000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092375342201729X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":5,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S092375342201729X"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2022.06.002","relation":{},"ISSN":["0923-7534"],"issn-type":[{"type":"print","value":"0923-7534"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fewer cetuximab-related skin-toxicities in colorectal cancer patients treated with encorafenib: a Yin and Yang effect of ERK paradoxical activation","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2022.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 European Society for Medical Oncology. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}